Medical Therapy. Efficacy or Lack of Efficacy

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants

Amit V. Krishnan, Victoria Freniere, Rakesh Sahni, Diana P. Vargas Chaves, Sankaran S. Krishnan, Dimitrios Savva, Usha S. KrishnanColumbia University Irving Medical Center and New York-Presbyterian Hospital. New York Medical College.United States ChildrenChildren 2024; DOI: 10.3390/children11060703 AbstractThis is a single-center retrospective study to assess the safety and tolerability of continuous inhaled iloprost use as rescue therapy […]

Safety and Tolerability of Continuous Inhaled Iloprost Therapy for Severe Pulmonary Hypertension in Neonates and Infants Read More »

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition

Xinyu Lia, Hui Li, Bo Feng, Xiaoyan Chen, Ting Chen, Jiafei Lu, Huating Xie, Nana Su, Houlin Chen, Chenghao Lou, Runxin Zhuang, Xi Chen, Shengwei Jin, Yu HaoSecond Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University. Ruijin Hospital and Shanghai Jiao Tong University School of Medicine. China Biomedicine and PharmacotherapyBiomed Pharmacother 2024; DOI: 10.1016/j.biopha.2024.117023

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition Read More »

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension

Brian S. Hernandez, Rod M. Shinozaki, R. Mark Grady, Andrea Drussa, Erica Jamro-Comer, Jinli Wang, Manish AggarwalWashington University School of Medicine. Loma Linda University Children’s Hospital. United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114116 AbstractObjective: To assess the effect of treating pulmonary hypertension (PH) in infants less than 1 year of age with systemic glucocorticoids while

Improvement in Echocardiographic and Diagnostic Biomarkers after Systemic Glucocorticoid Therapy in Infants with Pulmonary Hypertension Read More »

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial

Mandana Kashaki, Arash Mohazzab, Mohammad Radgoudarzi, Arash Bordbar, Sama DabbaghIran University of Medical Sciences. Shahid Akbar Abadi Hospital. Iran Pediatrics and NeonatologyPediatr Neonatol 2024; DOI: 10.1016/j.pedneo.2023.12.007 AbstractBackground: Persistent Pulmonary Hypertension of the newborn (PPHN) is characterized by sustained elevated Pulmonary Artery Pressure (PAP). Drug resistance and the adverse effects of current therapeutic agents warrant investigation of other

Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial Read More »

Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation

Michele Lioncino, Adelaide Fusco, Emanuele Monda, Diego Colonna, Martina Caiazza, Michelina Sibilio, Daniela Magri, Angela Carla Borrelli, Barbara D’Onofrio, Maria Luisa Mazzella, Rossella Colantuono, Maria Rosaria Arienzo, Berardo Sarubbi, Maria Giovanna Russo, Giovanni Chello, Giuseppe LimongelliUniversity of Campania “Luigi Vanvitelli” and Monaldi Hospital. University College of London and St. Bartholomew’s Hospital.Italy and United Kingdom GenesGenes

Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation Read More »

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients

Khaled Ahmed Shams, Dalia Monir Ellahony, Ahmed Fouad Halima, Rania Salah ElzayatHelwan University. Magdi Yacoub Foundation. Menoufia University.Egypt Egypt Heart JournalEgypt Heart J 2024; 76:DOI: 10.1186/s43044-024-00475-5 AbstractBackground: Children with ventricular septal defect (VSD) and large systemic-to-pulmonary shunts eventually develop pulmonary hypertension (PH). The perioperative management of patients with VSD and PH is quite troublesome and still debatable,

Effect of phosphodiesterase type 5 inhibitors on surgical outcome of ventricular septal defect and pulmonary hypertension patients Read More »

Management of Pulmonary Vascular Disease Associated with Congenital Left to Right Shunts: A Single Center Experience

Hythem Nawaytou, Ramya Lakkaraju, Leah Stevens, Vadiyala Mohan Reddy, Naveen Swami, Roberta L. Keller, David F. Teitel, Jeffrey R. FinemanUniversity of California,San Francisco.United States Journal of Thoracic and Cardiovascular SurgeryJ Thorac Cardiovasc Surg 2024; DOI: 10.1016/j.jtcvs.2024.05.007 AbstractObjective: To describe the course and outcomes of children under 18 with left-to-right (LR) shunts and pulmonary arterial hypertension (PAH) undergoing

Management of Pulmonary Vascular Disease Associated with Congenital Left to Right Shunts: A Single Center Experience Read More »

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial

Steven M. Kawut, Rui Feng, Susan S. Ellenberg, Roham Zamanian, Todd Bull, Murali Chakinala, Stephen C. Mathai, Anna Hemnes, Grace Lin, Margaret Doyle, Ruth Andrew, Margaret MacLean, Ioannis Stasinopoulos, Eric Austin, Angela DeMichele, Haochang Shou, Jasleen Minhas, Nianfu Song, Jude Moutchia, Corey E. VentetuoloUniversity of Pennsylvania Perelman School of Medicine. Stanford University Medical Center. University

Pulmonary Hypertension and Anastrozole (PHANTOM): A Randomized, Double-Blind, Placebo-Controlled Trial Read More »

Therapeutic effects of treat and repair strategy in pediatric patients with pulmonary arterial hypertension and simple congenital heart defects

Xiaofeng Wang, Shilin Wang, Zhongyuan Lu, Wenlong Wang, Xu WangFuWai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College.China Pulmonary CirculationPulm Circ 2024; 14: DOI: 10.1002/pul2.12387 AbstractSurgical indications for patients with pulmonary arterial hypertension (PAH) and congenital heart defects are controversial. The treat and repair strategy has demonstrated efficacy in adult populations, but there

Therapeutic effects of treat and repair strategy in pediatric patients with pulmonary arterial hypertension and simple congenital heart defects Read More »

Persistent Pulmonary Hypertension of the Newborn: Should Sildenafil and Inhaled Nitric Oxide at Medium Concentration Be the Standard of Treatment?

Ivan D. Florez, Luisa Parra-RodasUniversidad de Antioquia. McMaster University. Clínica Las Américas-AUNA. Universidad Pontificia Bolivariana.Columbia and Canada Critical Care MedicineCrit Care Med 2024; 52: 995-997DOI: 10.1097/CCM.0000000000006278 AbstractAbstract Not Available (Editorial) CategoryClass I. Persistent Pulmonary Hypertension of the NewbornMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh).

Persistent Pulmonary Hypertension of the Newborn: Should Sildenafil and Inhaled Nitric Oxide at Medium Concentration Be the Standard of Treatment? Read More »

Scroll to Top